Compare Stocks: LVTX, IPHA, TARA, and MDWD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPHA Innate Pharma	$1.59 +0.6%	$1.95	$1.17 ▼ $2.71	$176.52M	0.72	60,739 shs	133,729 shs
LVTX LAVA Therapeutics	$1.74	$1.72	$1.17 ▼ $1.83	$45.77M	0.5	187,834 shs	N/A
MDWD MediWound	$13.15 -2.7%	$13.55	$12.52 ▼ $20.03	$173.63M	0.09	90,151 shs	58,786 shs
TARA Protara Therapeutics	$2.56 -2.7%	$3.72	$2.53 ▼ $7.82	$155.42M	1.47	1.68 million shs	803,523 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPHA Innate Pharma	+0.63%	-0.63%	-23.56%	-13.59%	-20.70%
LVTX LAVA Therapeutics	0.00%	0.00%	0.00%	0.00%	+8.07%
MDWD MediWound	-2.66%	-4.71%	-1.05%	-10.54%	-25.75%
TARA Protara Therapeutics	-2.66%	-20.25%	-35.03%	-37.71%	-47.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPHA Innate Pharma	$1.59 +0.6%	$1.95	$1.17 ▼ $2.71	$176.52M	0.72	60,739 shs	133,729 shs
LVTX LAVA Therapeutics	$1.74	$1.72	$1.17 ▼ $1.83	$45.77M	0.5	187,834 shs	N/A
MDWD MediWound	$13.15 -2.7%	$13.55	$12.52 ▼ $20.03	$173.63M	0.09	90,151 shs	58,786 shs
TARA Protara Therapeutics	$2.56 -2.7%	$3.72	$2.53 ▼ $7.82	$155.42M	1.47	1.68 million shs	803,523 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPHA Innate Pharma	+0.63%	-0.63%	-23.56%	-13.59%	-20.70%
LVTX LAVA Therapeutics	0.00%	0.00%	0.00%	0.00%	+8.07%
MDWD MediWound	-2.66%	-4.71%	-1.05%	-10.54%	-25.75%
TARA Protara Therapeutics	-2.66%	-20.25%	-35.03%	-37.71%	-47.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPHA Innate Pharma	2.67	Moderate Buy	$6.67	319.29% Upside
LVTX LAVA Therapeutics	1.00	Sell	N/A	N/A
MDWD MediWound	2.50	Moderate Buy	$33.00	150.95% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	925.39% Upside

Current Analyst Ratings Breakdown

Latest LVTX, IPHA, TARA, and MDWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	MDWD MediWound	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2026	IPHA Innate Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/17/2026	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
9/16/2026	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/8/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$32.00 ➝ $30.00
8/12/2026	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/11/2026	IPHA Innate Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	IPHA Innate Pharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy ➝ Outperform
8/11/2026	IPHA Innate Pharma	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPHA Innate Pharma	$10.19M	17.43	N/A	N/A	($0.26) per share	-6.12
LVTX LAVA Therapeutics	$4.99M	9.17	N/A	N/A	$1.06 per share	1.64
MDWD MediWound	$11.86M	14.25	N/A	N/A	$3.40 per share	3.87
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$3.80 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPHA Innate Pharma	-$55.64M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	-$25.11M	-$0.86	N/A	N/A	N/A	N/A	-107.63%	-35.06%	N/A
MDWD MediWound	-$23.88M	-$1.80	N/A	N/A	N/A	-170.10%	-47.24%	-24.27%	11/19/2026 (Estimated)
TARA Protara Therapeutics	-$57.44M	-$1.35	N/A	N/A	N/A	N/A	-41.72%	-38.78%	11/9/2026 (Estimated)

Latest LVTX, IPHA, TARA, and MDWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	MDWD MediWound	-$0.7617	-$0.77	-$0.0083	-$0.77	$2.59 million	$3.09 million
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPHA Innate Pharma	N/A	0.60	N/A
LVTX LAVA Therapeutics	N/A	12.27	12.27
MDWD MediWound	N/A	2.32	2.09
TARA Protara Therapeutics	N/A	10.97	10.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPHA Innate Pharma	0.16%
LVTX LAVA Therapeutics	N/A
MDWD MediWound	46.83%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
IPHA Innate Pharma	31.89%
LVTX LAVA Therapeutics	9.50%
MDWD MediWound	9.20%
TARA Protara Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPHA Innate Pharma	163	111.72 million	76.09 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
MDWD MediWound	121	12.85 million	11.67 million	Optionable
TARA Protara Therapeutics	51	59.10 million	54.60 million	Optionable

LVTX, IPHA, TARA, and MDWD Headlines

Recent News About These Companies

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 23, 2026 | marketbeat.com

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch

August 21, 2026 | tipranks.com

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

August 12, 2026 | markets.businessinsider.com

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

August 11, 2026 | seekingalpha.com

What Makes Protara Therapeutics (TARA) a New Buy Stock

July 21, 2026 | zacks.com

Protara Therapeutics Announces Key Medical Leadership Transition

June 29, 2026 | tipranks.com

Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright

May 21, 2026 | theglobeandmail.com

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026 | globenewswire.com

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

May 19, 2026 | seekingalpha.com

Protara’s cell therapy shows treatment durability in mid-stage NMIBC study

May 19, 2026 | msn.com

Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program

May 18, 2026 | quiverquant.comQ

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026 | globenewswire.com

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of ...

May 15, 2026 | markets.businessinsider.com

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

May 15, 2026 | globenewswire.com

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

May 13, 2026 | globenewswire.com

One Protara Therapeutics Insider Raised Their Stake In The Previous Year

May 4, 2026 | finance.yahoo.com

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association ...

April 28, 2026 | markets.businessinsider.com

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

April 27, 2026 | globenewswire.com

Jacqueline Zummo Sells 22,598 Shares of Protara Therapeutics (NASDAQ:TARA) Stock

April 3, 2026 | insidertrades.com

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

March 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, IPHA, TARA, and MDWD Company Descriptions

Innate Pharma NASDAQ:IPHA

$1.59 +0.01 (+0.63%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.31%)

As of 10/6/2026 04:10 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

LAVA Therapeutics NASDAQ:LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

MediWound NASDAQ:MDWD

$13.15 -0.36 (-2.66%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$13.16 +0.01 (+0.08%)

As of 10/6/2026 07:30 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Protara Therapeutics NASDAQ:TARA

$2.56 -0.07 (-2.66%)

Closing price 10/6/2026 04:00 PM Eastern

Extended Trading

$2.56 0.00 (-0.20%)

As of 10/6/2026 07:30 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LVTX, IPHA, TARA, and MDWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LVTX, IPHA, TARA, and MDWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LVTX, IPHA, TARA, and MDWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, IPHA, TARA, and MDWD Company Descriptions

Innate Pharma NASDAQ:IPHA

LAVA Therapeutics NASDAQ:LVTX

MediWound NASDAQ:MDWD

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LVTX, IPHA, TARA, and MDWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LVTX, IPHA, TARA, and MDWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LVTX, IPHA, TARA, and MDWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LVTX, IPHA, TARA, and MDWD Company Descriptions

Innate Pharma NASDAQ:IPHA

LAVA Therapeutics NASDAQ:LVTX

MediWound NASDAQ:MDWD

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools